Personalis (PSNL) CEO Christopher Hall Buys $161K of Stock
Christopher Hall, CEO of Personalis, Inc., purchased 100,000 shares on June 26, 2026, at $1.61 per share.
Reviewed by automated data checks against the source filing. How we make and check alerts
Christopher Hall, Chief Executive Officer at Personalis, Inc. ($PSNL), bought 100,000 shares at an average price of $1.61, worth about $161,000, on June 26, 2026. The trade was reported to the SEC in a Form 4 filing.
Since the trade, $PSNL is up 10.1% after 1 week, down 8.0% after 1 month and up 20.2% to date (from the $13.02 close on Jun 26, 2026).
PSNL
Personalis, Inc.
Key Points
- Christopher Hall, CEO of Personalis, Inc., bought 100,000 shares at $1.61 each on June 26, 2026, totaling $161,000.
- Shares of Personalis, Inc. traded near $13.02 on Saturday with a market cap of approximately $1.36 billion.
- Analysts have set price targets ranging from $9 to $13, with Morgan Stanley maintaining a hold rating as of May 12, 2026.
Get $PSNL trade alerts by text
We text you when insiders, Congress or big funds trade $PSNL. Free.
Not investment advice. EarningsIQ is not a registered investment adviser, and this automated Personalis, Inc. alert may contain errors. Disclosures
Christopher Hall, the CEO of Personalis, Inc. (NasdaqGM: PSNL), recently acquired 100,000 shares of the company, paying $1.61 per share in an unplanned transaction on June 26, 2026. This purchase amounted to a total value of $161,000.
Insider Buying and Selling at Personalis, Inc.
On the same day, Aaron Tachibana, the CFO and COO, also bought 51,251 shares at an average price of $7.48, although he later sold the same amount under a planned transaction at $13.18 per share. Hall himself executed a planned sell of 100,000 shares at $13.15 per share after his initial purchase. These transactions highlight active trading by top executives.
Personalis, Inc. Stock Down 20.6%
Shares of Personalis, Inc. traded near $13.02 on Saturday. The company, which specializes in advanced cancer genomic tests, has a market cap of about $1.36 billion. It has no meaningful forward P/E ratio due to its lack of profitability, with an EPS of -$1.02. The stock's 52-week range has been between $3.84 and $13.37, and it has a beta of 2.276, indicating higher volatility compared to the market.
Analysts Set New Price Targets
Morgan Stanley maintained its hold rating on Personalis with a $9 price target on May 12, 2026. BTIG reiterated its buy rating with a target of $11 on May 11, 2026, while Needham supports a buy rating with a $12 target. The consensus among analysts suggests a mean target price of $10.86, with seven analysts covering the stock.
About Personalis, Inc.
Personalis, Inc. is a healthcare company headquartered in Fremont, California. It develops and sells genomic tests and services, focusing on cancer diagnostics and research. The company provides a range of advanced testing services, including liquid biopsy tests for cancer detection and monitoring. With a workforce of 259, Personalis collaborates with pharmaceutical and diagnostics companies, as well as research institutions, to advance personalized cancer therapies.
Bottom Line
Christopher Hall's purchase of Personalis shares indicates his confidence in the company's future. Investors often track such insider transactions for potential signals about company prospects. However, it's important to remember that these actions can be part of broader strategic decisions and may not reflect the company's current performance. Personalis continues to operate in the competitive field of cancer genomics, with analysts offering varied price targets.
Related Filing Alerts
Source: Christopher Hall's Form 4 filing on $PSNL (Jun 26, 2026). Find the original filing: PSNL Form 4 filings on SEC EDGAR. Written by software, not financial advice. How we make alerts